Finasteride for Benign Prostatic Hypertrophy
Finasteride (Proscar - Merck) has now been approved by the US Food and Drug Administration (FDA) for oral treatment of benign prostatic hyperplasia. A 4-aza-steroid, the drug is a specific inhibitor of steroid 5 -reductase, the enzyme that catalyzes conversion of testosterone to dihydrotestosterone. Dihydrotestosterone is required for development and maintenance of prostatic hypertrophy (JS Tenover, Endocrinol Metab Clin North Am, 20:893, 1991)....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Finasteride for Benign Prostatic Hypertrophy
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 878
Article Code: 878a
Date: September 4, 1992
Volume: 34
Pages: 83-84
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 878
Article Code: 878a
Date: September 4, 1992
Volume: 34
Pages: 83-84
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)